Cathay Capital Invests in BEBIG Medical
January 8, 2024
January 8, 2024 – Cathay Capital announced that it invested EUR 15 million in BEBIG Medical. This funding will be primarily used to expand the go-to-market of BEBIG Medical’s linear accelerator and intraoperative radiation therapy products, as well as to further deepen BEBIG Medical’s strategic deployment in radiation therapy.
Since it first exclusive investment in BEBIG Medical in 2021, Cathay Capital has leveraged its global resources to empower the company’s worldwide development strategy.
With technology of more than 40 years’ legacy, BEBIG Medical is a multinational company specializing in the R&D, manufacturing, and global sales of radiation therapy medical devices. The company operates factories in Germany, USA, and China, and has operational companies and offices in Germany, the USA, Singapore, China and India. BEBIG Medical’s product portfolio, including high-dose-rate brachytherapy, X-ray therapy products, and intraoperative radiation therapy devices, has more than 700 active installation bases across over 80 countries and regions via more than 70 global distributors.
BEBIG Medical will use the new funds to accelerate the global commercialization of its new linear accelerator and intraoperative radiation therapy, further deepening its footprints in the radiation therapy medical device sector.
Mr. George Chan, Chairman and CEO of BEBIG Medical, remarked, “Cathay Capital’s extensive global resources, with teams in 11 cities worldwide, aligns closely with BEBIG Medical’s global market strategy. In 2023, we signed agreements with RaySearch Laboratories and SHINVA, to strengthen the long-term cooperation of global business of Linear Accelerator (LINAC). Cathay Capital’s continued investment is a strong testimony to show investor’s confidence and support on us and this industry. This will empower us to dive deeper in the radiation therapy field. We look forward to working hand-in-hand with them to drive the development of the radiation therapy, offering more advanced effective and affordable medical solutions to everyone.”
Duan Lanchun, Managing Partner of Cathay Capital, stated, “With continuous technological innovation, product strength, and several successful international acquisitions, BEBIG Medical has rapidly grown, expanding its radiation therapy medical device product pipeline and global marketing network. We remain committed to actively integrating the abundant resources of the global medical industry ecosystem to further promote the BEBIG Medical’s solutions in global market, bringing more effective and affordable precision medical products to cancer patients.”
About BEBIG Medical
BEBIG Medical is a global provider of high-quality radiation therapy products for cancer treatment with a heritage of more than 40 years’ experience and proven clinical outcomes via strong and viable technology. Its current main products include high-dose-rate brachytherapy, X-ray therapy products, and intraoperative radiation therapy devices. BEBIG Medical has more than 700 active installation bases across over 80 countries and regions via more than 70 global distributors. With a team of professionals and offices in Europe, United States and Asia, the company is empowered to serve customers globally via affordable healthcare solutions. Learn more about BEBIG Medical via www.bebigmedical.com
About Cathay Capital
Cathay Capital is a global private equity and venture capital investment firm supporting healthcare, technology and consumer companies throughout North America, Europe, and Asia. The firm helps middle-market companies and startups navigate opportunities for growth, international expansion, and sustainable transformation. Cathay is the partner of choice for companies aspiring to lead markets and make a positive impact. Its platform connects people with global reach and local expertise – from investors and entrepreneurs to management teams and leading corporations – to share knowledge, the tools to scale and to transform businesses.
Founded in 2007 with a strong entrepreneurial heritage, Cathay Capital now manages more than $5.5 billion in assets. It has made over 250 investments in verticals, including healthcare, technology, and consumer, from offices in Paris, New York, San Francisco, Munich, Berlin, Madrid, Shanghai, Beijing, Shenzhen, and Singapore. For more information, visit: www.cathaycapital.com